Exercise and nicotinic acid delayed action drug - enduracin: application in outpatient rehabilitation of patients with ischemic heart disease


Aim. To evaluate efficacy of combined use of moderate exercise and nicotinic acid drug enduracin in
patients with coronary heart disease (CHD) with moderate dyslipidemia (DE).
Material and methods. The effects of exercise therapy alone, enduracin alone and their combination on physical performance (PP), hemodynamics, blood lipid spectrum and clinical course of CHD were studied in 93 CHD patients with moderate DE. The results were evaluated clinically after 1-year treatment.
Results. Combined used of exercise and enduracin in CHD patients showed its efficacy manifesting in improvement of PP, hemodynamics at rest and exercise test, left ventricular systolic function, clinical course, reduction of DE. Enduracin+exercise appeared more efficient than their use in monotherapy. Enduracin monotherapy had a positive action on PP, arterial pressure and anginal attacks frequency. Conclusion. Enduracin is recommended as monotherapy and in combination with moderate exercise in outpatient rehabilitation and secondary prophylaxis of CHD patients with moderate dyslipidemia and angina pectoris to relieve myocardial ischemia under exercise, to raise PP, improve lipid composition of blood and prevent maladaptive left ventricular remodeling.


  1. Оганов Р. Г., Поздняков Ю. М., Волков В. С. Ишемическая болезнь сердца. М.: Изд. Дом Синергия; 2002.
  2. O'Connor G. Т., Buring J. E., Yusuf S. et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80 (2): 234-244.
  3. Аронов Д. М. Лечение и профилактика атеросклероза. М.: Триада-Х; 2000.
  4. Hornig В., Mater V., Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93: 210-214.
  5. Schuler G., Hambrecht R., Schiert G. et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992; 86 (1): 1 - 11.
  6. Метелица В. И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: Медпрактика; 1996.
  7. Кухарчук В. В., Соловьев Е. Ю., Малышев П. П. и др. Влияние длительной монотерапии эндурацином на клинический и биохимический статус больных ишемической болезнью сердца. Тер. арх. 1997; 9: 41-45.
  8. Гудкова О. А. Антиишемические эффекты эндурацина (пролонгированной формы никотиновой кислоты) у больных коронарной болезнью сердца с гиперлипидемией: Дис. .. канд. мед. наук. М.; 2001.
  9. Пагава 3. Т. Влияние длительных физических тренировок на общую и локальную сократительную функцию миокарда левого желудочка больных, перенесших инфаркт миокарда: Автореф. дис. ... канд. мед. наук. М.; 1983.
  10. Оганов Р. Г., Киселева Н. Г., Аронов Д. М. и др. Применение эндурацина - пролонгированной формы никотиновой кислоты - в коррекции атерогенных дислипидемий. Кардиология 1993; 10: 54-59.
  11. Аронов Д. М., Перова Н. В., Ахмеджанов Н. М. Диагностика и лечение атерогенных дислипидемий: Метод, пособие для врачей. М.; 1996.
  12. Кеепап J. М., Вае С. Y., Fontaine P. L. et al. Treatment of hypercholesterolaemia: comparison on younger versus older patients using wax-matrix sustained-release niacin. JACC. 1992; 40: 12-18.



Abstract - 80


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2004 Oganov R.G., Aronov D.M., Krasnitsky V.В., Perova N.V., Olferyev A.M., Smolensky A.V., Novikova N.K., Vygodin V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies